Discontinuation is the unresolved problem of the GLP-1 era. Trial-based 22-28% mean weight loss numbers assume sustained dosing — and real-world claims data show most patients are not on these drugs long enough to come close.
Covered here: the Prime Therapeutics commercial claims analysis (cited in May 2026 Managed Healthcare Executive) showing just 8.1% three-year persistence on anti-obesity medications; the Medicaid 6-month data showing ~61% on-treatment at six months; the Oxford post-discontinuation regain study from January 2026 (weight regain faster than diet-program discontinuation); the 0.8 kg/month average regain rate for semaglutide and tirzepatide; and the PBM-led persistence interventions — Optum Rx Weight Engage, Rightway Care Complete, MedImpact GLP-1 Benefit 360 — embedding multidisciplinary support to lift persistence above the current floor.
Stories here cover the claims-data analyses, the prescriber-side maintenance protocols, and the policy implications for coverage decisions. See #real-world-evidence, #glp-1, and #pbm-access.
Researchers at Tufts University and UT Southwestern reported in Obesity Science & Practice on October 7, 2026 a pilot randomized trial of 39 adults who had lost weight on GLP-1 drugs and were stopping them, assigned to usual care (14), a digital wellness app (12), or medically tailored meals (13). Over the first four months off the drug, both the app and meal groups gained less weight than the control group, by 7.16 and 7.17 percentage points of body weight. Weight was an exploratory outcome, measured with Bluetooth scales at home, and the authors said larger and longer trials are needed.
Real-world evidence for Wegovy (semaglutide 2.4 mg once weekly subcutaneous injection) documents 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses. This compares to 14.9% weight loss in the STEP-1 registrational trial that supported the FDA approval. The gap is primarily adherence-driven: missed doses, titration pauses, insurance-driven dose changes, and stop-restart cycles flatten real-world curves relative to the tight-adherence STEP-1 population. Cleveland Clinic research confirmed that injectable obesity medications produce smaller weight loss in a real-world setting compared to randomized clinical trials, with the gap larger in patient subgroups facing financial barriers to consistent supply. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most manage to keep the weight off or continue losing by restarting treatment, switching medications (typically to tirzepatide or higher-dose Wegovy), or adopting lifestyle changes. Patient satisfaction is driven primarily by perceived effectiveness rather than tolerability: effective weight loss even with gastrointestinal side effects is associated with continued treatment adherence, while lower-efficacy responses lead to early discontinuation regardless of tolerability. The real-world evidence has implications for retatrutide's likely commercial trajectory: the 28.3% TRIUMPH-1 result may translate to 15-20% in real-world use depending on adherence patterns, which is still substantially above semaglutide's real-world 5.9-12% range.
TRIUMPH-1's safety profile landed alongside the efficacy headline. Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% on retatrutide 4 mg, 9 mg, and 12 mg respectively, versus 4.9% on placebo. The most common adverse events were nausea, diarrhea, constipation, and vomiting — generally mild-to-moderate, concentrated during dose escalation, and decreasing over time. The hepatic-enzyme signal that appeared in TRIUMPH-4 (December 2025) reappeared as transient ALT elevations in a subset of participants on 9 mg and 12 mg dosing, normalizing by week 24. Liver fat dropped >80% on 8-12 mg dosing, supporting the interpretation that the transient transaminitis reflects hepatic triglyceride mobilization rather than hepatotoxicity. The 12 mg discontinuation rate at 11.3% sits modestly above tirzepatide 15 mg in SURMOUNT-1 (~7%) and Wegovy 2.4 mg in STEP 1 (~6.5%) — a tolerability gap that prescribers and patients will weigh against the efficacy gain.
An ECO 2026 analysis covered May 18 by ScienceDaily examined 89,718 patients starting GLP-1 therapy — 75.6% semaglutide, 17.5% tirzepatide, 6.9% liraglutide — and stratified BMI change at year one. In the first year, 27% reduced BMI by less than 5%, 22.4% by 5-10%, 14.1% by 10-15%, and 15.8% by ≥15%, while 20.8% actually gained weight. Greater weight loss correlated with larger reductions in obesity-related risk endpoints; patients who gained weight after starting treatment faced worse health outcomes than untreated comparators in several measures.
Real-world data presented in the ECO 2026 cycle counters the trial-based efficacy headlines: a Prime Therapeutics commercial claims analysis (cited in the May 2026 Managed Healthcare Executive cover story) found just 8.1% of members persisted with anti-obesity GLP-1 medications for three years. A separate 6-month Medicaid persistence analysis showed roughly 61% staying on treatment at six months. The high attrition is driven primarily by GI tolerability, insurance turnover, and out-of-pocket costs after step-edit programs. For newer agents like semaglutide and tirzepatide, post-discontinuation weight regain averages 0.8 kg per month — projecting return to baseline by ~1.5 years. PBM programs (Optum Rx Weight Engage, Rightway, MedImpact GLP-1 Benefit 360) are now embedding multidisciplinary support to lift persistence above the current floor.
An NPR investigation found fewer than 1 in 4 patients stay on GLP-1 medications after a year, with most planning to restart later. Researchers warn that up to 40% of weight lost on GLP-1s is lean muscle, and cycling on and off the drugs may accelerate sarcopenia. When patients stop, fat regains rapidly while muscle recovery is uncertain.
New research finds approximately 25% of weight lost persists after GLP-1 discontinuation. Trajectories were similar across semaglutide, liraglutide, and tirzepatide.